NICE OKs Sarclisa & Mayzent For Funding In England, But Rejects Vindaqel

Scottish HTA Body Greenlights Bavencio, Brineura

The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.

Close up of diverse young people show thumbs up recommending good quality service, multiethnic clients or customers
NICE and the SMC OKd funding for a range of new therapies this week • Source: Shutterstock

The health technology assessment body for England, the National Institute for Health and Care Excellence, has this week issued several positive recommendations for the funding of medicines on the National Health Service.

One of them is Sanofi’s Sarclisa (isatuximab), the first monoclonal antibody therapy to be approved for marketing in the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe